PATENTSCOPE will be unavailable a few hours for maintenance reason on Monday 03.02.2020 at 10:00 AM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2011061527) COMBINATIONS COMPRISING A GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RESPIRATORY DISEASES
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

1. A pharmaceutical product comprising, in combination:

i) a first active ingredient which is a glucocorticoid receptor modulator selected from: 3-(5-{[(lR,2S)-2-[(2,2-difluoropropanoyl)amino]-l-(2,3-dihydro-l,4-benzodioxin-6-yl)propyl]oxy} - 1 H-indazol- 1 -yl)-N-[(3R)- 1 , 1 -dioxidotetrahydrothiophen-3 -yl]benzamide; 3-[5-({(lR,2S)-l-(4H-l,3-benzodioxin-7-yl)-2-[(2,2-difluoropropanoyl)amino]propyl}oxy)-1 H-indazol- 1 -yl] -N-(pyridin-3 -ylmethyl)benzamide;

3-(5-{[(lR,2S)-2-[(2,2-difluoropropanoyl)amino]-l-(2,3-dihydro-l,4-benzodioxin-6-yl)propyl]oxy} - 1 H-indazol- 1 -yl)-N-[(3 S)- 1 , 1 -dioxidotetrahydrothiophen-3-yl]benzamide; 3-[5-({(lR,2S)-l-(4H-l,3-Benzodioxin-7-yl)-2-[(2,2-difluoropropanoyl)amino]propyl}oxy)-1 H-indazol- 1 -yl] -N- [(3R)- 1 , 1 -dioxidotetrahydrothiophen-3 -yl]benzamide;

3-(5-{[(lR,2S)-2-[(2,2-difluoropropanoyl)amino]-l-(2,3-dihydro-l,4-benzodioxin-6-yl)propyl]oxy}-lH-indazol-l-yl)-N-[(3R)-tetrahydrofuran-3-yl]benzamide; and

3-(5-{[(lR,2S)-2-[(2,2-difluoropropanoyl)amino]-l-(2,3-dihydro-l,4-benzodioxin-6-yl)propyl]oxy } - 1 H-indazol- 1 -yl)-N-(pyridin-3 -ylmethyl)benzamide;

or a pharmaceutically acceptable salt thereof; and

ii) a second active ingredient selected from:

an Adenosine A2A receptor antagonist;

an anti-infective;

an antioxidant;

a β2 adrenoceptor agonist;

a CCR1 antagonist;

a chemokine antagonist (not CCR1);

a glucocorticosteroid;

a CRTh2 antagonist;

a DPI antagonist;

a formyl peptide receptor antagonist;

a Histone Deacetylase activator;

a chloride channel hCLCAl blocker

an Epithelial sodium channel blocker (ENAC blocker) ).

an Inter-cellular adhesion molecule 1 blocker (ICAM blocker);

an IKK2 kinase inhibitor;

a INK kinase inhibitor;

a cyclooxygenase inhibitor (COX inhibitor);

a lipoxygenase inhibitor;

a leukotriene receptor antagonist;

a MEK-1 kinase inhibitor

a myeloperoxidase inhibitor (MPO inhibitor);

a muscarinic antagonist;

a dual muscarinic antagonist^ adrenoceptor agonist (MABA compound);

a phosphodiesterase PDE4 inhibitor;

a phosphatidylinositol 3 (PD)-kinase γ inhibitor (PI 3 kinase γ inhibitor)

a peroxisome proliferator activated receptor agonist (PPARy agonist);

a protease inhibitor;

a p38 inhibitor;

a retinoic acid receptor modulator (RAR γ modulator)

a Statin;

a thromboxane antagonist; and

a vasodilator.

2. A pharmaceutical product according to claim 1, wherein the second active ingredient selected from:

a β2 adrenoceptor agonist;

a CCR1 antagonist;

a muscarinic antagonist;

a PDE4 inhibitor; and

a p38 inhibitor.

3. A pharmaceutical product according to claim 1, wherein the second active ingredient is N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-l,3-benzothiazol-7-yl)ethyl] amino }ethyl)-3-[2-(3-chlorophenyl)ethoxy]propanamide or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical product according to claim 1 , wherein the second active ingredient is N-Cyclohexyl-3-[2-(3-fluorophenyl)ethylamino]-N-[2-[2-(4-hydroxy-2-oxo-3H-l ,3-benzothiazol-7-yl)ethylamino]ethyl]propanamide, or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical product according to claim 1 , wherein the second active ingredient is N- {2-[((2iS)-3- {[ 1 -(4-chlorobenzyl)piperidin-4-yl] amino} -2-hydroxy-2-methylpropyl)oxy]-4-hydroxyphenyl}acetamide, or a pharmaceutically acceptable salt thereof .

6. A pharmaceutical product according to claim 1 , wherein the second active ingredient

hydroxypropyl]oxy} -4-[(methylamino)carbonyl]phenoxy} -2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical product according to claim 1 , wherein the second active ingredient is 6-fluoro-N-((ls,4s)-4-(6-fluoro-2,4-dioxo-l-(4'-(piperazin-l-ylmethyl)-biphenyl-3-yl)-l ,2-dihydropyrido[2,3-d]pyrimidin-3(4H)-yl)cyclohexyl)imidazo[l ,2-a]pyridine-2-carboxamide, or a pharmaceuticallyacceptable salt thereof.

8. A pharmaceutical product according to claim 1 , wherein the second active ingredient is N-cyclopropyl-3 -fluoro-4-methyl-5 - [3 -[ [ 1 -[2- [2-(methylamino)ethoxy]phenyl]

cyclopropyl] amino] -2-oxo-l(2H)-pyrazinyl]-benzamide, or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical product according to claim 1 , wherein the second active ingredient is (lR,3aS,3bS, 1 OaR, 1 ObS, 1 1 S, 12aS) 1 - {[(cyanomethyl)sulfanyl]carbonyl} -7-(4-fluorophenyl)-l l -hydroxy-10a,12a-dimethyl-l ,2,3,3a,3b,4,5,7, 10,10a, 10b,l 1 ,12, 12a-tetradecahydrocyclopenta[5,6]naphtho[l ,2-f]indazol-l-yl furan-2-carboxylate, or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical product according to any one of claims 1 to 9 wherein the first active ingredient is 3-(5-{[(lR,2S)-2-[(2,2-difluoropropanoyl)amino]-l-(2,3-dihydro-l,4-benzodioxin-6-yl)propyl]oxy} - 1 H-indazol- 1 -yl)-N- [(3 S)-l , 1 -dioxidotetrahydrothiophen-3 -yljbenzamide, or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical product according to any one of claims 1 to 9 wherein the first active ingredient is 3-(5-{[(lR,2S)-2-[(2,2-dif uoropropanoyl)amino]-l-(2,3-dihydro-l,4-benzodioxin-6-yl)propyl]oxy} - 1 H-indazol- 1 -yl)-N-[(3R)- 1 , 1 -dioxidotetrahydrothiophen-3 -yljbenzamide, or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical product according to any one of claims 1 to 9 wherein the first active ingredient is 3-[5-({(lR,2S)-l-(4H-l,3-Benzodioxin-7-yl)-2-[(2,2-difluoropropanoyl)amino]propyl} oxy)- 1 H-indazol- 1 -yl]-N-[(3R)- 1,1-dioxidotetrahydrothiophen-3-yl]benzamide, or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical product according to any one of claims 1 to 9 wherein the first active ingredient is 3-(5-{[(lR,2S)-2-[(2,2-dif uoropropanoyl)amino]-l-(2,3-dihydro-l,4-benzodioxin-6-yl)propyl]oxy}-lH-indazol-l-yl)-N-[(3R)-tetrahydrofuran-3-yl]benzamide, or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical product according to any one of claims 1 to 9 wherein the first active ingredient is 3-(5-{[(lR,2S)-2-[(2,2-dif uoropropanoyl)amino]-l-(2,3-dihydro-l,4-benzodioxin-6-yl)propyl]oxy}-lH-indazol-l-yl)-N-(pyridin-3-ylmethyl)benzamide, or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical product according to any one of claims 1 to 9 wherein the first active ingredient is 3-[5-({(lR,2S)-l-(4H-l,3-benzodioxin-7-yl)-2-[(2,2-difluoropropanoyl)amino]propyl} oxy)- 1 H-indazol- 1 -yl] -N-(pyridin-3 -ylmethyl)benzamide, or a pharmaceutically acceptable salt thereof.

16. Use of a product according to any one of claims 1 to 15 in the manufacture of a medicament for the treatment of a respiratory disease.

17. Use according to claim 16, wherein the respiratory disease is chronic obstructive pulmonary disease.

18. A method of treating a respiratory disease, which method comprises simultaneously, sequentially or separately administering:

(a) a (therapeutically effective) dose of a first active ingredient as defined in any one of claims 1 or 9 to 15; and

(b) a (therapeutically effective) dose of a second active ingredient as defined in claim 1; to a patient in need thereof.

19. A kit comprising a preparation of a first active ingredient as defined in any one of claims 1 or 9 to 15, and a preparation of a second active ingredient as defined in claim 1 and optionally instructions for the simultaneous, sequential or separate administration of the preparations to a patient in need thereof.

20. A pharmaceutical composition comprising, in admixture, a first active ingredient as defined in any one of claims 1 or 9 to 15 and a second active ingredient as defined in claim 1.